ARK Investment Management LLC Has $49.80 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

ARK Investment Management LLC lessened its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 4.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,216,365 shares of the company's stock after selling 106,967 shares during the quarter. ARK Investment Management LLC owned approximately 3.13% of Nurix Therapeutics worth $49,802,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the company. Amalgamated Bank raised its position in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company's stock valued at $49,000 after purchasing an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock valued at $54,000 after purchasing an additional 559 shares during the last quarter. ProShare Advisors LLC raised its position in Nurix Therapeutics by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company's stock valued at $176,000 after purchasing an additional 998 shares during the last quarter. ClariVest Asset Management LLC raised its position in Nurix Therapeutics by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company's stock valued at $1,318,000 after purchasing an additional 1,766 shares during the last quarter. Finally, Public Employees Retirement System of Ohio raised its position in Nurix Therapeutics by 3.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company's stock valued at $747,000 after purchasing an additional 1,820 shares during the last quarter.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 20,000 shares of the company's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.22, for a total value of $504,400.00. Following the sale, the chief financial officer now owns 31,002 shares in the company, valued at $781,870.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Christine Ring sold 9,870 shares of the company's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.01, for a total value of $246,848.70. Following the transaction, the insider now owns 24,592 shares of the company's stock, valued at approximately $615,045.92. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Houte Hans Van sold 20,000 shares of the company's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.22, for a total value of $504,400.00. Following the completion of the transaction, the chief financial officer now directly owns 31,002 shares in the company, valued at $781,870.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 57,321 shares of company stock worth $1,414,409 over the last 90 days. Company insiders own 7.20% of the company's stock.

Nurix Therapeutics Stock Performance

NRIX traded up $0.10 on Friday, hitting $27.34. 806,623 shares of the company were exchanged, compared to its average volume of 1,123,598. Nurix Therapeutics, Inc. has a 12 month low of $4.96 and a 12 month high of $28.42. The stock's fifty day moving average is $24.31 and its 200-day moving average is $20.59.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). The business had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on NRIX. Jefferies Financial Group began coverage on Nurix Therapeutics in a research report on Friday, October 11th. They set a "buy" rating and a $41.00 target price for the company. Robert W. Baird assumed coverage on Nurix Therapeutics in a research report on Friday, September 6th. They set an "outperform" rating and a $26.00 target price for the company. HC Wainwright lifted their price objective on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Truist Financial assumed coverage on Nurix Therapeutics in a research note on Wednesday, July 31st. They set a "buy" rating and a $36.00 price objective for the company. Finally, Royal Bank of Canada decreased their price objective on Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, Nurix Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $29.40.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.